For which patients with resected NSCLC will you offer adjuvant atezolizumab after completion of cisplatin-based adjuvant chemotherapy?
Based off IMpower010, which patients with Stage IB-IIIA resected NSCLC will you offer adjuvant atezolizumab after completion of cisplatin-based adjuvant chemotherapy?
Join Mednetto vote and see how they answered.
The initial results of IMpower010 were presented by Dr. @Dr. First Last at ASCO 2021. This study demonstrated that adjuvant atezolizumab following surgical resection and adjuvant platinum based chemotherapy improved disease free survival in stage II-IIIA NSCLC patients with tumors with PDL1 expressi...
Join for free or sign in to see the full answer
There were several primary endpoints in IMpower010 that met statistical significance including disease free survival (DFS) in the PDL1 positive (≥1%) stage II-IIIA subgroup (DFS HR 0.66, 95% CI 0.50-0.88, p=0.0039) and all patients stage II-IIIA subgroup (DFS HR 0.79, 95% CI 0.64-0.96, p=0.020). Tho...
Join for free or sign in to see the full answer
IMpower010 demonstrated a DFS benefit for patients with resected stage II-IIIA NSCLC expressing PD-L1 1% or greater (HR 0.66, 95% CI 0.50-0.88, p=0.00039). The secondary endpoint of DFS in patients with II-IIIA NSCLC high PD-L1 expression at 50% or more was met with an impressive HR of 0.43 (95% CI ...
Join for free or sign in to see the full answer
This is typically decided by our medical oncology colleagues.
Join for free or sign in to see the full answer